During medical emergencies, when decisions must be made quickly, knowing how blood thinners are affecting a person’s ability ...

Daiichi Sankyo has launched its Lixiana product onto the UK market, where it becomes the fourth novel oral anti-coagulant (NOAC) available to treat and prevent clot-related disorders.

The EPIC-CAD Trial July 2, 2025 | Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

Financial Valuation Company is profitable The company's revenue grew in March quarter by 10.11% from Rs 465.85 crore to Rs 423.07 crore, year-on-year The company's profit declined by 28.16% year ...